DaVita (DVA) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual meeting scheduled for June 5, 2025, with virtual attendance available for shareholders.
Shareholders are encouraged to review proxy materials and vote by June 4, 2025, or June 3, 2025, for retirement plan shares.
Voting matters and shareholder proposals
Election of nine directors is on the agenda, with all nominees recommended by the board.
Ratification of KPMG LLP as the independent registered public accounting firm for fiscal year 2025 is proposed.
Advisory vote on executive compensation for named executive officers is included.
Proxy holders may vote on other business as may properly come before the meeting.
Board of directors and corporate governance
Board recommends all director nominees for election at the annual meeting.
Director nominees include Pamela M. Arway, Barbara J. Desoer, Jason M. Hollar, Gregory J. Moore, Dennis W. Pullin, Javier J. Rodriguez, Adam H. Schechter, Wendy L. Schoppert, and Phyllis R. Yale.
Latest events from DaVita
- 2026 OI growth driven by U.S. dialysis, international, and IKC, with margin focus and stable mix.DVA
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - 2026 guidance targets 3.2% OI and 33% EPS growth, with strong IKC gains and robust cash flow.DVA
Q4 20253 Feb 2026 - Q2 revenue hit $3.19B, net income $223M, and 2024 guidance was raised on RPT growth.DVA
Q2 20242 Feb 2026 - Q3 2024 revenue reached $3.264B with strong cash flow and ongoing cost headwinds.DVA
Q3 202418 Jan 2026 - Revenue strength and operational improvements offset by volume and supply challenges, with 2025 outlook stable.DVA
UBS Global Healthcare Conference 202414 Jan 2026 - 2024 delivered record earnings and cash flow; 2025 targets steady EPS growth amid cost headwinds.DVA
Q4 20248 Jan 2026 - Flat treatment growth, cost inflation, and regulatory shifts shape 2024 outlook.DVA
Barclays 27th Annual Global Healthcare Conference26 Dec 2025 - Strong financial results, board refreshment, and ESG leadership drive 2025 proxy agenda.DVA
Proxy Filing1 Dec 2025 - Q2 2025 delivered revenue growth and capital returns despite cyber and cost headwinds.DVA
Q2 202523 Nov 2025